Literature DB >> 7299130

Intracellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages.

C A Nacy, M S Meltzer, E J Leonard, D J Wyler.   

Abstract

C3H/HeN resident peritoneal macrophages in suspension culture supported continuous replication of L. tropica amastigotes; the total number of intracellular parasites increased 8- to 10-fold over 96 hr in culture. Lymphokine treatment of macrophages markedly affected intracellular replication of the Leishmania. Cultures treated with lymphokines before exposure to L. tropica were more resistant to infection, and 35% fewer cells contained intracellular amastigotes compared to medium-treated controls. Lymphokine-pretreated cells that became infected also inhibited the replication of intracellular amastigotes. Macrophage cultures treated with lymphokines after infection exhibited potent microbicidal activity; 75 to 80% of macrophages were free of intracellular parasites by 72 hr. Fractionation of lymphokine supernatants by Sephadex G-100 demonstrated 3 areas of activity for the induction of macrophage intracellular killing (130,000, 45,000, less than or equal to 10,000 daltons); one of these activity peaks (45,000-m.w. lymphokine(s)) also induced increased resistance to infection with L. tropica.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7299130

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Susceptibility of inbred mice to Leishmania major infection: genetic analysis of macrophage activation and innate resistance to disease in individual progeny of P/J (susceptible) and C3H/HeN (resistant) mice.

Authors:  A H Fortier; A Tong; C A Nacy
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

2.  Malnutrition alters the innate immune response and increases early visceralization following Leishmania donovani infection.

Authors:  G M Anstead; B Chandrasekar; W Zhao; J Yang; L E Perez; P C Melby
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

Authors:  D Frommel; B W Ogunkolade; I Vouldoukis; L Monjour
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

4.  Semiautomated assessment of in vitro activity of potential antileishmanial drugs.

Authors:  J D Berman; J V Gallalee
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  Increased myelopoiesis during Leishmania major infection in mice: generation of 'safe targets', a possible way to evade the effector immune mechanism.

Authors:  A M Mirkovich; A Galelli; A C Allison; F Z Modabber
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

6.  Lymphokine-induced inhibition of growth of Eimeria bovis and Eimeria papillata (Apicomplexa) in cultured bovine monocytes.

Authors:  C A Speer; D W Reduker; D E Burgess; W M Whitmire; G A Splitter
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

7.  Differential inhibition of macrophage microbicidal activity by liposomes.

Authors:  M J Gilbreath; G M Swartz; C R Alving; C A Nacy; D L Hoover; M S Meltzer
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

8.  Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor/interferon.

Authors:  R G Titus; A Kelso; J A Louis
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

9.  Comparison of the effect of various stimuli on the leishmaniacidal capacity of human monocytes in vitro.

Authors:  J Passwell; R Shor; G Keren; G Messer; J El-On
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

10.  Murine peritoneal macrophages activated by the mycobacterial 65-kilodalton heat shock protein express enhanced microbicidal activity in vitro.

Authors:  W E Peetermans; J A Langermans; M E van der Hulst; J D van Embden; R van Furth
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.